Bristol Trial Finds Tocilizumab Lifts Depression in 54% of 30 Resistant Cases
Updated
Updated · SciTechDaily · Jun 1
Bristol Trial Finds Tocilizumab Lifts Depression in 54% of 30 Resistant Cases
3 articles · Updated · SciTechDaily · Jun 1
A 30-patient randomized trial found tocilizumab improved symptoms in adults with moderate-to-severe, treatment-resistant depression and low-grade inflammation after four weeks.
Remission reached 54% in the tocilizumab group versus 31% with placebo, giving a number needed to treat of 5, compared with about 7 for standard SSRIs.
The drug targets the IL-6 inflammatory pathway rather than serotonin or other brain chemicals, reflecting evidence that roughly one-third of depressed patients show elevated inflammation markers.
Researchers said the proof-of-concept study was too small for strong statistical certainty, but the signal supports a larger phase III trial before routine clinical use.
Could a risky arthritis drug be the key to unlocking treatment-resistant depression?
If depression isn't just brain chemistry, could our immune system hold the cure?
Tocilizumab Achieves 54% Remission in Treatment-Resistant Depression: Pilot Trial Signals New Era for Immunotherapy
Overview
Recent research has revealed that inflammation may play a key role in depression for about one in three patients, leading scientists to explore new treatments that target the immune system. Building on this, a pilot clinical trial led by the University of Bristol tested tocilizumab, an anti-inflammatory drug, for people with treatment-resistant depression. The study found that tocilizumab could help reduce depressive symptoms, especially in those with elevated inflammatory markers. These findings open the door to more personalized depression care, focusing on immunotherapies that address the underlying biology of the illness.